Explore the words cloud of the AcTaferon project. It provides you a very rough idea of what is the project "AcTaferon" about.
The following table provides information about the project.
Coordinator |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Organization address contact info |
Coordinator Country | France [FR] |
Project website | https://www.cordis.europa.eu/project/rcn/209395_en.html |
Total cost | 144˙230 € |
EC max contribution | 144˙230 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2016 |
Funding Scheme | MSCA-IF-EF-ST |
Starting year | 2017 |
Duration (year-month-day) | from 2017-05-01 to 2018-12-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS | FR (PARIS) | coordinator | 144˙230.00 |
Based on their antiviral and antitumor effect, type I interferons (IFNs) were believed to be the miracle drug to tackle viruses and cancer. However, clinical IFN applications remained limited due to severe side effects resulting from widespread cellular sensitivity to IFN, which limits the administrable doses. Hence, the drug concentration at the desired infection or tumor site is often too low to be fully therapeutic efficient. AcTaferon (Activated-by-Targeting interferon), co-developed by Prof. Uzé, circumvents these obstacles. By fusing an IFN mutant with strongly reduced receptor binding affinity to a targeting moiety that recognizes a surface marker on specific cells, AcTaferon remains inactive “en route” through the body and unveils its biological activity only on specific target cells. Robust tumor regression without side effects and preliminary antiviral effects underscore the huge clinical potential of AcTaferon to fight cancer and viral diseases. By combining the AcTaferon and influenza expertise of Prof. Uzé and Prof. Saelens, respectively, this interdisciplinary project offers the opportunity to broaden the innovative AcTaferon therapeutic strategy from the cancer to the viral infection field. Influenza A was selected as a pilot target as seasonal influenza A epidemics and occasional pandemics remain a serious health threat causing substantial morbidity and mortality. Influenza A-targeted AcTaferons will be developed and analyzed in relevant in vitro and in vivo models. Eventually, all knowledge will be transferred to Orionis, a company that will implement the AcTaferon technology to develop novel drugs. My background on the intracellular processes that negatively regulate cytokine receptors and hence influence the cellular sensitivity to a (therapeutic) cytokine is an asset to this project. I will be able to extend my fundamental research experience with applied cytokine research, which may extend into a new academic or industrial research pipeline.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ACTAFERON" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ACTAFERON" are provided by the European Opendata Portal: CORDIS opendata.